Eli Lilly

News

Illustration of a nerve cell on a colored background with light effects

Lilly to buy private biotech Disarm Therapeutics for up to $...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

News

Lilly pauses COVID-19 antibody trial after factory hits trou...

Eli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found serious quality control problems at the plant, according to press reports.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

News

Eli Lilly and Gilead's combination cuts COVID-19 recovery ti...

Eli Lilly’s Olumiant (baricitinib) has a significant effect on recovery from COVID-19 when combined with Gilead Veklury (remdesivir), according to a large trial backed by funding from the U

News

Lilly asks FDA for emergency clearance for COVID-19 antibody...

Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial.

News

BioNTech, Lilly shore up manufacturing capacity for their CO...

With vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the capacity to make them at scale, as new deals for BioNTech and Eli Lilly this

Lilly to buy private biotech Disarm Therapeutics for up to $...

Lilly pauses COVID-19 antibody trial after factory hits trou...

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Eli Lilly and Gilead's combination cuts COVID-19 recovery ti...

Lilly asks FDA for emergency clearance for COVID-19 antibody...

BioNTech, Lilly shore up manufacturing capacity for their CO...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks